Development of auto antigen-specific regulatory T cells for diabetes immunotherapy

Immune Network

Volumn 16, Issue 5, 2016, Pages 281-285

  Song, Jianxun ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Diabetes; Immunotherapy; Regulatory T cells; Stem cells; T cells; Tolerance

Indexed keywords

AUTOANTIGEN; ELONGATION FACTOR 2; NOTCH RECEPTOR; SURVIVIN;

ANTIGEN SPECIFICITY; CELL FATE; DIABETES MELLITUS; GENETIC TRANSDUCTION; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INTRACELLULAR SIGNALING; LIGAND BINDING; LYMPHOCYTE DIFFERENTIATION; NOTCH SIGNALING; PANCREAS ISLET BETA CELL; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; STEM CELL TRANSPLANTATION;

EID: 85018499271     PISSN: 15982629     EISSN: 20926685     Source Type: Journal    
DOI: 10.4110/in.2016.16.5.281     Document Type: Review

References (36)

1. Bluestone, J. A., J. H. Buckner, M. Fitch, S. E. Gitelman, S. Gupta, M. K. Hellerstein, K. C. Herold, A. Lares, M. R. Lee, K. Li, W. Liu, S. A. Long, L. M. Masiello, V. Nguyen, A. L. Putnam, M. Rieck, P. H. Sayre, and Q. Tang. 2015. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci. Transl. Med. 7: 315ra189.
2. Mahne, A. E., J. E. Klementowicz, A. Chou, V. Nguyen, and Q. Tang. 2015. Therapeutic regulatory T cells subvert effector T cell function in inflamed islets to halt autoimmune diabetes. J. Immunol. 194: 3147-3155.
3. Hossain, D. M., A. K. Panda, A. Manna, S. Mohanty, P. Bhattacharjee, S. Bhattacharyya, T. Saha, S. Chakraborty, R. K. Kar, T. Das, S. Chatterjee, and G. Sa. 2013. FoxP3 acts as a cotranscription factor with STAT3 in tumor-induced regulatory T cells. Immunity 39: 1057-1069.
4. + medullary thymic epithelial cells. Nat. Immunol. 8: 351-358.
5. Haque, R., F. Lei, X. Xiong, Y. Wu, and J. Song. 2010. FoxP3 and Bcl-xL cooperatively promote regulatory T cell persistence and prevention of arthritis development. Arthritis Res. Ther. 12: R66.
6. van Herwijnen, M. J., L. Wieten, Z. R. van der, P. J. van Kooten, J. P. Wagenaar-Hilbers, A. Hoek, B. den, I, S. M. Anderton, M. Singh, H. D. Meiring, C. A. van Els, E. W. van, and F. Broere. 2012. Regulatory T cells that recognize a ubiquitous stress-inducible self-antigen are long-lived suppressors of autoimmune arthritis. Proc. Natl. Acad. Sci. U. S. A. 109: 14134-14139.
7. Wright, G. P., C. A. Notley, S. A. Xue, G. M. Bendle, A. Holler, T. N. Schumacher, M. R. Ehrenstein, and H. J. Stauss. 2009. Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis. Proc. Natl. Acad. Sci. U. S. A. 106: 19078-19083.
8. Sela, U., P. Olds, A. Park, S. J. Schlesinger, and R. M. Steinman. 2011. Dendritic cells induce antigen-specific regulatory T cells that prevent graft versus host disease and persist in mice. J. Exp. Med. 208: 2489-2496.
9. Bacher, P., O. Kniemeyer, A. Schonbrunn, B. Sawitzki, M. Assenmacher, E. Rietschel, A. Steinbach, O. A. Cornely, A. A. Brakhage, A. Thiel, and A. Scheffold. 2014. Antigen-specific expansion of human regulatory T cells as a major tolerance mechanism against mucosal fungi. Mucosal Immunol. 7: 916-928.
10. Nguyen, T. L., N. L. Sullivan, M. Ebel, R. M. Teague, and R. J. DiPaolo. 2011. Antigen-specific TGF-beta-induced regulatory T cells secrete chemokines, regulate T cell trafficking, and suppress ongoing autoimmunity. J. Immunol. 187: 1745-1753.
11. Haque, M., J. Song, K. Fino, P. Sandhu, X. Song, F. Lei, S. Zheng, B. Ni, D. Fang, and J. Song. 2016. Stem cell-derived tissue-associated regulatory T cells ameliorate the development of autoimmunity. Sci. Rep. 6: 20588.
12. Van Belle, T. L., E. Ling, C. Haase, D. Bresson, B. Urso, and M. G. von Herrath. 2013. NKG2D blockade facilitates diabetes prevention by antigen-specific Tregs in a virus-induced model of diabetes. J. Autoimmun. 40: 66-73.
13. Takiishi, T., H. Korf, T. L. Van Belle, S. Robert, F. A. Grieco, S. Caluwaerts, L. Galleri, I. Spagnuolo, L. Steidler, H. K. Van, P. Demetter, C. Wasserfall, M. A. Atkinson, F. Dotta, P. Rottiers, C. Gysemans, and C. Mathieu. 2012. Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice. J. Clin. Invest. 122: 1717-1725.
14. + T cell cultures upon polyclonal stimulation ex vivo. J. Immunol. 181: 8767-8775.
15. + T helper cells is controlled by the transcription factor eos. Immunity 38: 998-1012.
16. Perro, M., J. Tsang, S. A. Xue, D. Escors, M. Cesco-Gaspere, C. Pospori, L. Gao, D. Hart, M. Collins, H. Stauss, and E. C. Morris. 2010. Generation of multi-functional antigen-specific human T-cells by lentiviral TCR gene transfer. Gene Ther. 17: 721-732.
17. Porter, D. L., B. L. Levine, M. Kalos, A. Bagg, and C. H. June. 2011. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365: 725-733.
18. Bendle, G. M., C. Linnemann, A. I. Hooijkaas, L. Bies, M. A. de Witte, A. Jorritsma, A. D. Kaiser, N. Pouw, R. Debets, E. Kieback, W. Uckert, J. Y. Song, J. B. Haanen, and T. N. Schumacher. 2010. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat. Med. 16: 565-70.
19. Gratz, I. K., H. A. Truong, S. H. Yang, M. M. Maurano, K. Lee, A. K. Abbas, and M. D. Rosenblum. 2013. Cutting Edge: memory regulatory t cells require IL-7 and not IL-2 for their maintenance in peripheral tissues. J. Immunol. 190: 4483-4487.
20. Kuball, J., M. L. Dossett, M. Wolfl, W. Y. Ho, R. H. Voss, C. Fowler, and P. D. Greenberg. 2007. Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood 109: 2331-2338.
21. van Loenen, M. M., B. R. de, A. L. Amir, R. S. Hagedoorn, G. L. Volbeda, R. Willemze, J. J. van Rood, J. H. Falkenburg, and M. H. Heemskerk. 2010. Mixed T cell receptor dimers harbor potentially harmful neoreactivity. Proc. Natl. Acad. Sci. U. S. A. 107: 10972-10977.
22. Kim, Y. C., A. H. Zhang, Y. Su, S. A. Rieder, R. J. Rossi, R. A. Ettinger, K. P. Pratt, E. M. Shevach, and D. W. Scott. 2015. Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses. Blood 125: 1107-1115.
23. Haque, R., F. Lei, X. Xiong, Y. Bian, B. Zhao, Y. Wu, and J. Song. 2012. Programming of regulatory T cells from pluripotent stem cells and prevention of autoimmunity. J. Immunol. 189: 1228-1236.
24. Kim, J. B., V. Sebastiano, G. Wu, M. J. rauzo-Bravo, P. Sasse, L. Gentile, K. Ko, D. Ruau, M. Ehrich, B. D. van den, J. Meyer, K. Hubner, C. Bernemann, C. Ortmeier, M. Zenke, B. K. Fleischmann, H. Zaehres, and H. R. Scholer. 2009. Oct4-induced pluripotency in adult neural stem cells. Cell 136: 411-419.
25. Zhao, T., Z. N. Zhang, Z. Rong, and Y. Xu. 2011. Immunogenicity of induced pluripotent stem cells. Nature 474: 212-215.
26. Lei, F., B. Zhao, R. Haque, X. Xiong, L. Budgeon, N. D. Christensen, Y. Wu, and J. Song. 2011. In vivo programming of tumor antigen-specific T lymphocytes from pluripotent stem cells to promote cancer immunosurveillance. Cancer Res. 71: 4742-4747.
27. Haque, M., J. Song, K. Fino, P. Sandhu, Y. Wang, B. Ni, D. Fang, and J. Song. 2016. Melanoma immunotherapy in mice using genetically engineered pluripotent stem cells. Cell Transplant. 25: 811-827.
28. Themeli, M., C. C. Kloss, G. Ciriello, V. D. Fedorov, F. Perna, M. Gonen, and M. Sadelain. 2013. Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat. Biotechnol. 31: 928-933.
29. Vizcardo, R., K. Masuda, D. Yamada, T. Ikawa, K. Shimizu, S. Fujii, H. Koseki, and H. Kawamoto. 2013. Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8(+) T cells. Cell Stem Cell 12: 31-36.
30. + T cells generated from induced pluripotent stem cells triggers regressions of large tumors along with immunological memory. Cancer Res. 76: 3473-3483.
31. Dervovic, D. D., H. C. Liang, J. L. Cannons, A. R. Elford, M. Mohtashami, P. S. Ohashi, P. L. Schwartzberg, and J. C. Zuniga-Pflucker. 2013. Cellular and molecular requirements for the selection of in vitro-generated CD8 T cells reveal a role for Notch. J. Immunol. 191: 1704-1715.
32. Wendorff, A. A., U. Koch, F. T. Wunderlich, S. Wirth, C. Dubey, J. C. Bruning, H. R. MacDonald, and F. Radtke. 2010. Hes1 is a critical but context-dependent mediator of canonical Notch signaling in lymphocyte development and transformation. Immunity 33: 671-684.
33. Guo, Y., I. Maillard, S. Chakraborti, E. V. Rothenberg, and N. A. Speck. 2008. Core binding factors are necessary for natural killer cell development and cooperate with Notch signaling during T-cell specification. Blood 112: 480-492.
34. Lei, F., J. Song, R. Haque, X. Xiong, D. Fang, Y. Wu, S. M. Lens, M. Croft, and J. Song. 2013. Transgenic expression of survivin compensates for OX40-deficiency in driving Th2 development and allergic inflammation. Eur. J. Immunol. 43: 1914-1924.
35. Cheng, Y., X. Ren, Y. Yuan, Y. Shan, L. Li, X. Chen, L. Zhang, Y. Takahashi, J. W. Yang, B. Han, J. Liao, Y. Li, H. Harvey, A. Ryazanov, G. P. Robertson, G. Wan, D. Liu, A. F. Chen, Y. Tao, and J. M. Yang. 2016. eEF-2 kinase is a critical regulator of Warburg effect through controlling PP2A-A synthesis. Oncogene doi: 10.1038/onc.2016.166.
36. Di, S. A., S. K. Tey, G. Dotti, Y. Fujita, A. Kennedy-Nasser, C. Martinez, K. Straathof, E. Liu, A. G. Durett, B. Grilley, H. Liu, C. R. Cruz, B. Savoldo, A. P. Gee, J. Schindler, R. A. Krance, H. E. Heslop, D. M. Spencer, C. M. Rooney, and M. K. Brenner. 2011. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365: 1673-1683.